Stable reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-mediated modulation of gene expression

Analytical Biochemistry

Volumn 414, Issue 1, 2011, Pages 77-83

  Gijsbers, Linda ^a   Man, Hai Yen ^b   Kloet, Samantha K ^a   De Haan, Laura H J ^a   Keijer, Jaap ^a   Rietjens, Ivonne M C M ^a   Van Der Burg, Bart ^b   Aarts, Jac M M J G ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b BIODETECTION SYSTEMS B V   (Netherlands)

Author keywords

Human U2OS cells; Peroxisome proliferator activated receptor (PPAR ); Peroxisome proliferator responsive element (PPRE); Stable luciferase reporter cell line; Thiazolidinediones

Indexed keywords

CELL CULTURE; DRUG PRODUCTS; GENE EXPRESSION;

CONCENTRATION-DEPENDENT; LOW-COST MEASUREMENTS; LUCIFERASE ACTIVITIES; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR; PEROXISOME PROLIFERATORS; REPORTER CELL LINE; REPORTER GENE ASSAYS; THIAZOLIDINEDIONES;

MOLECULAR BIOLOGY;

15 DEOXY DELTA 12,14 PROSTAGLANDIN J2; 2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; CIGLITAZONE; FENOFIBRATE; LUCIFERASE; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PIOGLITAZONE; PIRINIXIC ACID; PROSTAGLANDIN J2; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; DNA DETERMINATION; GENE EXPRESSION; HUMAN; HUMAN CELL; LUCIFERASE REPORTER GENE ASSAY; PRIORITY JOURNAL;

EID: 79955676346     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2011.02.032     Document Type: Article

References (69)

1. J. Berger, D.E. Moller, The mechanisms of action of PPARs, Annu. Rev. Med. 53 (2002) 409-435. (Pubitemid 34177889)
2. L. Michalik, W. Wahli, Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions, Curr. Opin. Biotechnol. 10 (1999) 564-570.
3. Y. Barak, M.C. Nelson, E.S. Ong, Y.Z. Jones, P. Ruiz-Lozano, K.R. Chien, A. Koder, R.M. Evans, PPARγ is required for placental, cardiac, and adipose tissue development, Mol. Cell 4 (1999) 585-595. (Pubitemid 29531138)
4. P. Tontonoz, E. Hu, R.A. Graves, A.I. Budavari, B.M. Spiegelman, MPPARγ2: tissue-specific regulator of an adipocyte enhancer, Genes Dev. 8 (1994) 1224-1234.
5. P. Tontonoz, E. Hu, B.M. Spiegelman, Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor, Cell 79 (1994) 1147-1156.
6. S. Kersten, B. Desvergne, W. Wahli, Roles of PPARs in health and disease, Nature 405 (2000) 421-424. (Pubitemid 30367411)
7. M. Imran, B. Ilyas, Deepanjali, S.A. Khan, Recent thiazolidinediones as antidiabetics, J. Sci. Ind. Res. 66 (2007) 99-109. (Pubitemid 46277216)
8. M. Wang, S. Tafuri, Modulation of PPARγ activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis, J. Cell. Biochem. 89 (2003) 38-47.
9. T.M. O'Moore-Sullivan, J.B. Prins, Thiazolidinediones and type 2 diabetes: new drugs for an old disease, Med. J. Aust. 176 (2002) 381-386.
10. C.E. Quinn, P.K. Hamilton, C.J. Lockhart, G.E. McVeigh, Thiazolidinediones: effects on insulin resistance and the cardiovascular system, Br. J. Pharmacol. 153 (2008) 636-645.
11. H. Yki-Jarvinen, Thiazolidinediones, N. Engl. J. Med. 351 (2004) 1106-1118.
12. 4 pathway to inflammation control, Nature 384 (1996) 39-43.
13. C. Jiang, A.T. Ting, B. Seed, PPAR-γ agonists inhibit production of monocyte inflammatory cytokines, Nature 391 (1998) 82-86. (Pubitemid 28079219)
14. M. Ricote, A.C. Li, T.M. Willson, C.J. Kelly, C.K. Glass, The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, Nature 391 (1998) 79-82. (Pubitemid 28079218)
15. B. Staels, W. Koenig, A. Habib, R. Merval, M. Lebret, I.P. Torra, P. Delerive, A. Fadel, G. Chinetti, J.-C. Fruchart, J. Najib, J. Maclouf, A. Tedgui, Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators, Nature 393 (1998) 790-793. (Pubitemid 28299490)
16. J.H. Chung, A.Y. Seo, S.W. Chung, M.K. Kim, C. Leeuwenburgh, B.P. Yu, H.Y. Chung, Molecular mechanism of PPAR in the regulation of age-related inflammation, Ageing Res. Rev. 7 (2008) 126-136.
17. A. Szanto, L. Nagy, The many faces of PPARγ: anti-inflammatory by any means? Immunobiology 213 (2008) 789-803.
18. G. Landreth, Q. Jiang, S. Mandrekar, M. Heneka, PPARγ agonists as therapeutics for the treatment of Alzheimer's disease, Neurotherapeutics 5 (2008) 481-489. (Pubitemid 351952487)
19. M.G. Belvisi, D.J. Hele, M.A. Birrell, Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation, Eur. J. Pharmacol. 533 (2006) 101-109.
20. R. Chen, F. Liang, J. Moriya, J. Yamakawa, T. Takahashi, L. Shen, T. Kanda, Peroxisome proliferator-activated receptors (PPARs) and their agonists for hypertension and heart failure: are the reagents beneficial or harmful? Int. J. Cardiol. 130 (2008) 131-139.
21. V.T. Chetty, A.M. Sharma, Can PPARγ agonists have a role in the management of obesity-related hypertension? Vasc. Pharmacol. 45 (2006) 46-53. (Pubitemid 43963484)
22. A.D. Dobrian, S.D. Schriver, A.A. Khraibi, R.L. Prewitt, Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity, Hypertension 43 (2004) 48-56. (Pubitemid 38031910)
23. P.A. Sarafidis, A.N. Lasaridis, Actions of peroxisome proliferator-activated receptor-γ agonists explaining a possible blood pressure-lowering effect, Am. J. Hypertens. 19 (2006) 646-653.
24. C.D. Allred, D.R. Talbert, R.C. Southard, X. Wang, M.W. Kilgore, PPARγ1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells, J. Nutr. 138 (2008) 250-256. (Pubitemid 351213635)
25. S. Han, J. Roman, Peroxisome proliferator-activated receptor γ: a novel target for cancer therapeutics? Anti-Cancer Drugs 18 (2007) 237-244.
26. L. Michalik, B. Desvergne, W. Wahli, Peroxisome-proliferator-activated receptors and cancers: complex stories, Nat. Rev. Cancer 4 (2004) 61-70.
27. F. Ondrey, Peroxisome proliferator-activated receptor c pathway targeting in carcinogenesis: implications for chemoprevention, Clin. Cancer Res. 15 (2009) 2-8.
28. A. Elbrecht, Y. Chen, C.A. Cullinan, N. Hayes, M.D. Leibowitz, D.E. Moller, J. Berger, Molecular cloning, expression, and characterization of human peroxisome proliferator activated receptors γ1 and γ2, Biochem. Biophys. Res. Commun. 224 (1996) 431-437.
29. L. Fajas, D. Auboeuf, E. Raspé, K. Schoonjans, A.-M. Lefebvre, R. Saladin, J. Najib, M. Laville, J.-C. Fruchart, S. Deeb, A. Vidal-Puig, J. Flier, M.R. Briggs, B. Staels, H. Vidal, J. Auwerx, The organization, promoter analysis, and expression of the human PPARγ gene, J. Biol. Chem. 272 (1997) 18779-18789. (Pubitemid 27318225)
30. A. Vidal-Puig, M. Jimenez-Linan, B.B. Lowell, A. Hamann, E. Hu, B. Spiegelman, J.S. Flier, D.E. Moller, Regulation of PPAR γ gene expression by nutrition and obesity in rodents, J. Clin. Invest. 97 (1996) 2553-2561.
31. A.J. Vidal-Puig, R.V. Considine, M. Jimenez-Liñan, A. Werman, W.J. Pories, J.F. Caro, J.S. Flier, Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids, J. Clin. Invest. 99 (1997) 2416-2422. (Pubitemid 27227719)
32. E. Mueller, S. Drori, A. Aiyer, J. Yie, P. Sarraf, H. Chen, S. Hauser, E.D. Rosen, K. Ge, R.G. Roeder, B.M. Spiegelman, Genetic analysis of adipogenesis through peroxisome proliferator-activated receptor γ isoforms, J. Biol. Chem. 277 (2002) 41925-41930.
33. D. Ren, T.N. Collingwood, E.J. Rebar, A.P. Wolffe, H.S. Camp, PPARγ knockdown by engineered transcription factors: exogenous PPARγ2 but not PPARγ1 reactivates adipogenesis, Genes Dev. 16 (2002) 27-32. (Pubitemid 34049635)
34. G. Medina-Gomez, S. Virtue, C. Lelliott, R. Boiani, M. Campbell, C. Christodoulides, C. Perrin, M. Jimenez-Linan, M. Blount, J. Dixon, D. Zahn, R.R. Thresher, S. Aparicio, M. Carlton, W.H. Colledge, M.I. Kettunen, T. Seppänen-Laakso, J.K. Sethi, S. O'Rahilly, K. Brindle, S. Cinti, M. Orešič, R. Burcelin, A. Vidal-Puig, The link between nutritional status and insulin sensitivity is dependent on the adipocyte-specific peroxisome proliferatoractivated receptor-γ2 isoform, Diabetes 54 (2005) 1706-1716. (Pubitemid 40770761)
35. E.H. Jeninga, O. van Beekum, A.D.J. van Dijk, N. Hamers, B.I. Hendriks-Stegeman, A.M.J.J. Bonvin, R. Berger, E. Kalkhoven, Impaired peroxisome proliferator-activated receptor γ function through mutation of a conserved salt bridge (R425C) in familial partial lipodystrophy, Mol. Endocrinol. 21 (2007) 1049-1065.
36. E. Lucarelli, L. Sangiorgi, V. Maini, G. Lattanzi, S. Marmiroli, M. Reggiani, M. Mordenti, G.A. Gobbi, F. Scrimieri, A.Z. Bertoja, P. Picci, Troglitazone affects survival of human osteosarcoma cells, Int. J. Cancer 98 (2002) 344-351. (Pubitemid 34188676)
37. E. Sonneveld, C. van den Brink, B. van der Leede, R. Schulkes, M. Petkovich, B. van der Burg, P. van der Saag, Human retinoic acid (RA) 4-hydroxylase (CYP26) is highly specific for all-trans-RA and can be induced through RA receptors in human breast and colon carcinoma cells, Cell Growth Differ. 9 (1998) 629-637. (Pubitemid 28367252)
38. B.M. Forman, P. Tontonoz, J. Chen, R.P. Brun, B.M. Spiegelman, R.M. Evans, 15-Deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ, Cell 83 (1995) 803-812.
39. E. Sonneveld, H.J. Jansen, J.A.C. Riteco, A. Brouwer, B. van der Burg, Development of androgen- and estrogen-responsive bioassays: members of a panel of human cell line-based highly selective steroid-responsive bioassays, Toxicol. Sci. 83 (2005) 136-148.
40. M.E. Quaedackers, C.E. Van Den Brink, S. Wissink, R.H.M.M. Schreurs, J-A. Gustafsson, P.T. Van Der Saag, B. Van Der Burg, 4-Hydroxytamoxifen transrepresses nuclear factor-κB activity in human osteoblastic U2-OS cells through estrogen receptor (ER)α, and not through ERβ, Endocrinology 142 (2001) 1156-1166. (Pubitemid 32203725)
41. M.J. Reginato, S.T. Bailey, S.L. Krakow, C. Minami, S. Ishii, H. Tanaka, M.A. Lazar, A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor γ-activating properties, J. Biol. Chem. 273 (1998) 32679-32684.
42. P. Sertznig, M. Seifert, W. Tilgen, J. Reichrath, Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer, J. Cell. Physiol. 212 (2007) 1-12. (Pubitemid 46876399)
43. T.M. Willson, J.E. Cobb, D.J. Cowan, R.W. Wiethe, I.D. Correa, S.R. Prakash, K.D. Beck, L.B. Moore, S.A. Kliewer, J.M. Lehmann, The structure - activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones, J. Med. Chem. 39 (1996) 665-668.
44. L.M. Leesnitzer, D.J. Parks, R.K. Bledsoe, J.E. Cobb, J.L. Collins, T.G. Consler, R.G. Davis, E.A. Hull-Ryde, J.M. Lenhard, L. Patel, K.D. Plunket, J.L. Shenk, J.B. Stimmel, C. Therapontos, T.M. Willson, S.G. Blanchard, Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662, Biochemistry 41 (2002) 6640-6650. (Pubitemid 34547354)
45. G. Lee, F. Elwood, J. McNally, J. Weiszmann, M. Lindstrom, K. Amaral, M. Nakamura, S. Miao, P. Cao, R.M. Learned, J.-L. Chen, Y. Li, T0070907, a selective ligand for peroxisome proliferator-activated receptor γ, functions as an antagonist of biochemical and cellular activities, J. Biol. Chem. 277 (2002) 19649-19657.
46. B.M. Forman, J. Chen, R.M. Evans, Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ, Proc. Natl. Acad. Sci. USA 94 (1997) 4312-4317.
47. K.S. Frederiksen, E.M. Wulff, P. Sauerberg, J.P. Mogensen, L. Jeppesen, J. Fleckner, Prediction of PPAR-α ligand-mediated physiological changes using gene expression profiles, J. Lipid Res. 45 (2004) 592-601. (Pubitemid 38338007)
48. M. Seimandi, G. Lemaire, A. Pillon, A. Perrin, I. Carlavan, J.J. Voegel, F. Vignon, J.-C. Nicolas, P. Balaguer, Differential responses of PPARα, PPARδ, and PPARγ reporter cell lines to selective PPAR synthetic ligands, Anal. Biochem. 344 (2005) 8-15. (Pubitemid 41569372)
49. B.R. Henke, S.G. Blanchard, M.F. Brackeen, K.K. Brown, J.E. Cobb, J.L. Collins, W.W. Harrington, M.A. Hashim, E.A. Hull-Ryde, I. Kaldor, S.A. Kliewer, D.H. Lake, L.M. Leesnitzer, J.M. Lehmann, J.M. Lenhard, L.A. Orband-Miller, J.F. Miller, R.A. Mook, S.A. Noble, W. Oliver, D.J. Parks, K.D. Plunket, J.R. Szewczyk, T.M. Willson, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents, J. Med. Chem. 41 (1998) 5020-5036.
50. M. Mueller, A. Jungbauer, Culinary plants, herbs, and spices: a rich source of PPARγ ligands,, Food Chem. 117 (2009) 660-667.
51. M.S. Venkatraman, A. Chittiboyina, J. Meingassner, C.I. Ho, J. Varani, C.N. Ellis, M.A. Avery, H.A. Pershadsingh, T.W. Kurtz, S.C. Benson, F-lipoic acid-based PPARγ agonists for treating inflammatory skin diseases, Arch. Dermatol. Res. 296 (2004) 97-104. (Pubitemid 39150295)
52. T.M. Willson, P.J. Brown, D.D. Sternbach, B.R. Henke, The PPARs: from orphan receptors to drug discovery, J. Med. Chem. 43 (2000) 527-550.
53. W.R. Oliver, J.L. Shenk, M.R. Snaith, C.S. Russell, K.D. Plunket, N.L. Bodkin, M.C. Lewis, D.A. Winegar, M.L. Sznaidman, M.H. Lambert, H.E. Xu, D.D. Sternbach, S.A. Kliewer, B.C. Hansen, T.M. Willson, A selective peroxisome proliferator-activated receptor d agonist promotes reverse cholesterol transport, Proc. Natl. Acad. Sci. USA 98 (2001) 5306-5311. (Pubitemid 32397124)
54. R. Pereira, C. Gaudon, B. Iglesias, P. Germain, H. Gronemeyer, A.R. de Lera, Synthesis of the PPARβ/δ-selective agonist GW501516 and C4-thiazole-substituted analogs, Bioorg. Med. Chem. Lett. 16 (2006) 49-54. (Pubitemid 41625639)
55. M.L. Sznaidman, C.D. Haffner, P.R. Maloney, A. Fivush, E. Chao, D. Goreham, M.L. Sierra, C. LeGrumelec, H.E. Xu, V.G. Montana, M.H. Lambert, T.M. Willson, W.R. Oliver, D.D. Sternbach, Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ): synthesis and biological activity, Bioorg. Med. Chem. Lett. 13 (2003) 1517-1521.
56. K. Yamamoto, T. Itoh, D. Abe, M. Shimizu, T. Kanda, T. Koyama, M. Nishikawa, T. Tamai, H. Ooizumi, S. Yamada, Identification of putative metabolites of docosahexaenoic acid as potent PPARγ agonists and antidiabetic agents, Bioorg. Med. Chem. Lett. 15 (2005) 517-522.
57. Promega, pGL4 Luciferase Reporter Vectors Technical Manual, Promega, Madison, WI, 2009.
58. A. Aranda, A. Pascual, Nuclear hormone receptors and gene expression, Physiol. Rev. 81 (2001) 1269-1304.
59. C. Blanquart, O. Barbier, J.C. Fruchart, B. Staels, C. Glineur, Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation, J. Steroid Biochem. Mol. Biol. 85 (2003) 267-273. (Pubitemid 37011102)
60. T. Leff, S.T. Mathews, H.S. Camp, Peroxisome proliferator-activated receptor-γ and its role in the development and treatment of diabetes, Exp. Diabetes Res. 5 (2004) 11.
61. A. Werman, A. Hollenberg, G. Solanes, C. Bjørbæk, A.J. Vidal-Puig, J.S. Flier, Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor γ (PPARγ), J. Biol. Chem. 272 (1997) 20230-20235.
62. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Willson, S.A. Kliewer, An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ), J. Biol. Chem. 270 (1995) 12953-12956.
63. C. Giaginis, S. Theocharis, A. Tsantili-Kakoulidou, Investigation of the lipophilic behaviour of some thiazolidinediones: relationships with PPAR-γ activity, J. Chromatogr. B 857 (2007) 181-187. (Pubitemid 47454564)
64. P.W. Young, D.R. Buckle, B.C.C. Cantello, H. Chapman, J.C. Clapham, P.J. Coyle, D. Haigh, R.M. Hindley, J.C. Holder, H. Kallender, A.J. Latter, K.W.M. Lawrie, D. Mossakowska, G.J. Murphy, L.R. Cox, S.A. Smith, Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ, J. Pharmacol. Exp. Ther. 284 (1998) 751-759. (Pubitemid 28086668)
65. M. Awais, M. Sato, Y. Umezawa, A fluorescent indicator to visualize ligand-induced receptor/coactivator interactions for screening of peroxisome proliferator-activated receptor γ ligands in living cells, Biosens. Bioelectron. 22 (2007) 2564-2569.
66. J.D. Burton, D.M. Goldenberg, R.D. Blumenthal, Potential of peroxisome proliferator-activated receptor gamma antagonist compounds as therapeutic agents for a wide range of cancer types, PPAR Res. 2008 (2008) 494161.
67. Q. Chen, J. Chen, T. Sun, J. Shen, X. Shen, H. Jiang, A yeast two-hybrid technology-based system for the discovery of PPARγ agonist and antagonist, Anal. Biochem. 335 (2004) 253-259.
68. S.A. Kliewer, J.M. Lenhard, T.M. Willson, I. Patel, D.C. Morris, J.M. Lehmann, A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation, Cell 83 (1995) 813-819. (Pubitemid 3006325)
69. G. Krey, O. Braissant, F. L'Horset, E. Kalkhoven, M. Perroud, M.G. Parker, W. Wahli, Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay, Mol. Endocrinol. 11 (1997) 779-791. (Pubitemid 27225305)